drugset

drugset / Trial / NCT00004156

Vaccine Therapy in Treating Patients With Breast Cancer

NCT00004156 ↗

Phase 1 Completed 45 enrolled Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.

Timeline

Start: 1999-05
Primary completion: 2008-06
Completion: —

Publications

Results Musselli C, Ragupathi G, Gilewski T, Panageas KS, Spinat Y, Livingston PO. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int J Cancer. 2002 Feb 10;97(5):660-7. doi: 10.1002/ijc.10081.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MUC1-KLH vaccine	Vaccine	—	Subcutaneous
Background	QS-21	Other / unclassified	—	Subcutaneous

Indications